Pituitary adenylate cyclase activating polypeptide in animal models of neurodegenerative disorders - Implications for Huntington and Parkinson's diseases

D. Reglodi, A. Tamás, A. Somogyvári-Vigh

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The present study summarizes results obtained with PACAP treatment in models of neurodegenerative diseases. The data show that PACAP protected a significant number of neurons in quinolinic acid- and 6-hydoxydopamine-induced lesions, which correlated with the less severe behavioral symptoms. These effects may have clinical implications in Huntington and Parkinson's diseases.

Original languageEnglish
Pages (from-to)311-315
Number of pages5
JournalLetters in Drug Design and Discovery
Volume2
Issue number4
DOIs
Publication statusPublished - Jun 2005

Fingerprint

Pituitary Adenylate Cyclase-Activating Polypeptide
Huntington Disease
Neurodegenerative Diseases
Parkinson Disease
Animal Models
Quinolinic Acid
Behavioral Symptoms
Neurons

Keywords

  • Huntington
  • Neurodegeneration
  • Neuroprotection
  • PACAP
  • Parkinson

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Drug Discovery
  • Molecular Medicine

Cite this

@article{96d7774cb060432689c54e701073c171,
title = "Pituitary adenylate cyclase activating polypeptide in animal models of neurodegenerative disorders - Implications for Huntington and Parkinson's diseases",
abstract = "The present study summarizes results obtained with PACAP treatment in models of neurodegenerative diseases. The data show that PACAP protected a significant number of neurons in quinolinic acid- and 6-hydoxydopamine-induced lesions, which correlated with the less severe behavioral symptoms. These effects may have clinical implications in Huntington and Parkinson's diseases.",
keywords = "Huntington, Neurodegeneration, Neuroprotection, PACAP, Parkinson",
author = "D. Reglodi and A. Tam{\'a}s and A. Somogyv{\'a}ri-Vigh",
year = "2005",
month = "6",
doi = "10.2174/1570180054038440",
language = "English",
volume = "2",
pages = "311--315",
journal = "Letters in Drug Design and Discovery",
issn = "1570-1808",
publisher = "Bentham Science Publishers B.V.",
number = "4",

}

TY - JOUR

T1 - Pituitary adenylate cyclase activating polypeptide in animal models of neurodegenerative disorders - Implications for Huntington and Parkinson's diseases

AU - Reglodi, D.

AU - Tamás, A.

AU - Somogyvári-Vigh, A.

PY - 2005/6

Y1 - 2005/6

N2 - The present study summarizes results obtained with PACAP treatment in models of neurodegenerative diseases. The data show that PACAP protected a significant number of neurons in quinolinic acid- and 6-hydoxydopamine-induced lesions, which correlated with the less severe behavioral symptoms. These effects may have clinical implications in Huntington and Parkinson's diseases.

AB - The present study summarizes results obtained with PACAP treatment in models of neurodegenerative diseases. The data show that PACAP protected a significant number of neurons in quinolinic acid- and 6-hydoxydopamine-induced lesions, which correlated with the less severe behavioral symptoms. These effects may have clinical implications in Huntington and Parkinson's diseases.

KW - Huntington

KW - Neurodegeneration

KW - Neuroprotection

KW - PACAP

KW - Parkinson

UR - http://www.scopus.com/inward/record.url?scp=20644466656&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20644466656&partnerID=8YFLogxK

U2 - 10.2174/1570180054038440

DO - 10.2174/1570180054038440

M3 - Article

AN - SCOPUS:20644466656

VL - 2

SP - 311

EP - 315

JO - Letters in Drug Design and Discovery

JF - Letters in Drug Design and Discovery

SN - 1570-1808

IS - 4

ER -